查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593037

靜脈鐵劑市場：按產品和應用分類 - 全球預測 2025-2030

Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose), Application (Cancer, Chronic Kidney Disease, Inflammatory Bowel Disease) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年靜脈注射鐵劑市值為28.9億美元，預計2024年將達到31.6億美元，複合年成長率為9.65%，預計到2030年將達到55億美元。

靜脈鐵劑市場的範圍包括經由靜脈途徑給藥的鐵鹽的開發和應用，以治療缺鐵和貧血，特別是當口服給藥失敗或不可行時。由於慢性腎臟病、癌症和其他導致貧血的疾病的盛行率不斷增加，因此需要有效管理患者的鐵水平，從而推動了該市場的發展。靜脈補鐵對於解決需要快速補充鐵質的嚴重缺鐵患者的貧血至關重要，例如在手術、癌症治療和透析環境中，以及在醫院、診所和治療中心，我們正在擴大靜脈補鐵的應用。關鍵的成長要素包括提高安全性和有效性的配方的進步、醫院方案的更多採用以及更容易患貧血的老年人口的增加。利用夥伴關係關係擴大產品系列、改善銷售管道並增加新興市場的可近性存在潛在機會。建議重點研發，開發副作用最小的新劑型，能獲得病人接受，擴大市場。然而，其使用也存在一些限制，包括嚴格的法律規範、高成本以及過敏反應等潛在副作用。此外，競爭對手的專利保護策略也為新參與企業帶來了市場進入挑戰。創新將致力於創造更安全、更有效的輸送機制，並開拓貧血以外的新治療適應症。該市場競爭激烈，其特點是製藥公司和醫療保健提供者之間不斷合作，以改善患者的治療結果。為了取得成功，公司必須預測監管變化，在藥物開發中優先考慮患者安全，並利用生物技術的進步來保持競爭優勢。與醫療保健專業人士合作，以獲取有關靜脈補鐵劑的益處和風險的真實世界證據和透明溝通，對於增強市場信心和成長至關重要。

主要市場統計
基準年[2023] 28.9億美元
預測年份 [2024] 31.6億美元
預測年份 [2030] 55億美元
複合年成長率（%） 9.65%

市場動態：快速發展的靜脈鐵劑市場的關鍵市場洞察

供需的動態交互作用正在改變靜脈鐵劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性腎臟病盛行率不斷上升
    • 需要預防孕婦貧血並改善孕產婦和分娩結果
    • 醫療保健領域投資，醫療費用增加
  • 市場限制因素
    • 醫藥品認證過程嚴格規定
  • 市場機會
    • 加大開發新藥研究力度
    • 改善供應鏈和分銷網路
  • 市場挑戰
    • 與靜脈鐵劑相關的副作用

波特五力：駕馭靜脈鐵劑市場的策略工具

波特的五力框架是了解靜脈鐵劑市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對靜脈鐵劑市場的影響

外部宏觀環境因素對靜脈鐵劑市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解靜脈鐵劑市場的競爭狀況

對靜脈鐵劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位靜脈注射基質鐵市場供應商績效評估

FPNV定位矩陣是評估靜脈鐵劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪靜脈鐵劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，靜脈鐵劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性腎臟病盛行率增加
      • 需要預防孕婦貧血並改善孕產婦和分娩結果
      • 醫療保健領域投資，藥品支出增加
    • 抑制因素
      • 嚴格藥品核准流程規定
    • 機會
      • 加大開發新藥研究力度
      • 改善供應鏈和分銷網路
    • 任務
      • 與靜脈鐵劑相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章靜脈鐵劑市場：依產品

  • Ferric carboxymaltose
  • 聚葡萄糖鐵
  • 蔗糖鐵

第7章 靜脈鐵劑市場：依應用分類

  • 癌症
  • 慢性腎臟病
  • 發炎性腸道疾病

第8章 北美、南美靜脈鐵劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太靜脈鐵劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東、非洲靜脈注射鐵劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories Inc
  • Actavis, Inc.
  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • American Regent. Inc.
  • Baxter International Inc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Ltd.
  • Fresenius Medical Care AG & Co.
  • Galenica Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi AG
  • Shield Therapeutics PLC
  • Vifor Pharma Management Ltd.
Product Code: MRR-22146147736D

The Intravenous Iron Drugs Market was valued at USD 2.89 billion in 2023, expected to reach USD 3.16 billion in 2024, and is projected to grow at a CAGR of 9.65%, to USD 5.50 billion by 2030.

The scope of the intravenous iron drugs market encompasses the development and application of iron salts administered via intravenous routes to treat iron deficiency and anemia, particularly when oral administration fails or isn't feasible. This market is primarily driven by the growing prevalence of chronic kidney disease, cancer, and other conditions leading to anemia, necessitating efficient management of iron levels in patients. Intravenous iron drugs are essential in addressing anemia in those with severe iron-deficiency where rapid replenishment of iron is required, such as in surgical, cancer treatment, or dialysis settings, broadening its application across hospitals, clinics, and treatment centers. Key growth influencers include advancements in drug formulations enhancing safety and efficacy, increasing adoption in hospital protocols, and a rising geriatric population more prone to anemia. Potential opportunities lie in expanding product portfolios, improving distribution channels, and leveraging partnerships to enhance accessibility in emerging markets. A recommendation is to focus on R&D to develop new formulations that minimize side effects, thus broadening patient acceptance and market reach. However, limitations include stringent regulatory frameworks, high costs, and potential side effects like allergic reactions, which can limit usage. Additionally, competitors' patent protection strategies pose challenges to market entry for new players. Innovation can be directed towards creating safer, more efficient delivery mechanisms and exploring new therapeutic indications beyond anemia. The market is competitive, characterized by continuous collaboration between pharmaceutical companies and healthcare providers to improve patient outcomes. To succeed, companies must anticipate regulatory changes, prioritize patient safety in drug development, and harness advances in biotechnology to maintain competitive advantage. Collaboration with healthcare professionals for real-world evidence and transparent communication about benefits and risks of intravenous iron drugs are essential for fostering market confidence and growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.89 billion
Estimated Year [2024] USD 3.16 billion
Forecast Year [2030] USD 5.50 billion
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intravenous Iron Drugs Market

The Intravenous Iron Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic kidney disease
    • Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
    • Investment in the healthcare sector, higher spending on medicine
  • Market Restraints
    • Stringent regulations with the drug approval process
  • Market Opportunities
    • Increasing research in new drug development
    • Improvements in supply chain and distribution network
  • Market Challenges
    • Side-effects related to Intravenous Iron drugs

Porter's Five Forces: A Strategic Tool for Navigating the Intravenous Iron Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intravenous Iron Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intravenous Iron Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intravenous Iron Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intravenous Iron Drugs Market

A detailed market share analysis in the Intravenous Iron Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intravenous Iron Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intravenous Iron Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intravenous Iron Drugs Market

A strategic analysis of the Intravenous Iron Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Iron Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc, Actavis, Inc., Allergan, Inc., AMAG Pharmaceuticals. Inc., American Regent. Inc., Baxter International Inc, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Fresenius Medical Care AG & Co., Galenica Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pharmacosmos A/S, Rockwell Medical, Inc., Sanofi AG, Shield Therapeutics PLC, and Vifor Pharma Management Ltd..

Market Segmentation & Coverage

This research report categorizes the Intravenous Iron Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Ferric Carboxymaltose, Iron Dextran, and Iron Sucrose.
  • Based on Application, market is studied across Cancer, Chronic Kidney Disease, and Inflammatory Bowel Disease.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic kidney disease
      • 5.1.1.2. Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
      • 5.1.1.3. Investment in the healthcare sector, higher spending on medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations with the drug approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research in new drug development
      • 5.1.3.2. Improvements in supply chain and distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects related to Intravenous Iron drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intravenous Iron Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Ferric Carboxymaltose
  • 6.3. Iron Dextran
  • 6.4. Iron Sucrose

7. Intravenous Iron Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Chronic Kidney Disease
  • 7.4. Inflammatory Bowel Disease

8. Americas Intravenous Iron Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Intravenous Iron Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Intravenous Iron Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc
  • 2. Actavis, Inc.
  • 3. Allergan, Inc.
  • 4. AMAG Pharmaceuticals. Inc.
  • 5. American Regent. Inc.
  • 6. Baxter International Inc
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Daiichi Sankyo Company, Ltd.
  • 10. Fresenius Medical Care AG & Co.
  • 11. Galenica Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Pharmacosmos A/S
  • 16. Rockwell Medical, Inc.
  • 17. Sanofi AG
  • 18. Shield Therapeutics PLC
  • 19. Vifor Pharma Management Ltd.

LIST OF FIGURES

  • FIGURE 1. INTRAVENOUS IRON DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INTRAVENOUS IRON DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IRON DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRAVENOUS IRON DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2023